Belantamab mafodotin

How it works

It targets B-cell maturation antigen (BCMA) on myeloma cells and delivers a cytotoxic agent intracellularly, leading to tumour cell death.

Prescribing in practice

• It commonly causes ocular toxicity, including keratopathy and visual changes, so regular ophthalmic examination is required and dosing is adjusted accordingly.
• It is administered by intravenous infusion under specialist haematology-oncology supervision.
• Infusion-related reactions and thrombocytopenia can occur and require monitoring.

Monitoring

Perform ophthalmic assessments before and during treatment and monitor blood counts, with dose modification guided by current prescribing references.

Counselling the patient

• Attend all eye examinations and report any blurred vision, dry eyes or visual changes.
• Use lubricating eye drops as advised and avoid contact lenses unless directed.

Evidence & guidelines

Belantamab mafodotin is supported by clinical trial evidence in heavily pretreated multiple myeloma, with ocular monitoring central to its safe use.